Changing the pace of progress in lung cancer survival

We are the Lung Ambition Alliance

Lung cancer claims a life every 18 seconds and is the leading cause of cancer-related death globally.1 Less than 20% of patients are alive five years on from initial diagnosis.2

The Lung Ambition Alliance, a global coalition with partners across disciplines in over 50 countries, was formed to combat lung cancer through accelerating innovation and driving forward meaningful improvements for people with lung cancer.

Patients are at the heart of everything we do, and we understand that every patient deserves the highest quality care.

Our ambition is to eliminate lung cancer as a cause of death, and our first step is to double five-year survival by 2025.

What is our approach?

We work together to accelerate advances and improve survival for people with lung cancer. We do this by advocating for improved approaches in three key areas:


We must increase early diagnosis and ensure the implementation of screening programs. We need to raise awareness of the strong evidence for screening, address other barriers to early detection and increase diagnostic accuracy.[3,4]


We must enable a paradigm-shift to earlier intervention, when potential for cure is greater, and place increased emphasis on early detection of relapse.[5,6] We believe precision medicine may be even more effective if utilized earlier in the course of the disease.[7] We are prioritizing the validation of surrogate endpoints which may enable better targeting of tumor characteristics and accelerate the development of new treatments.[8]


We must urgently close the gap in cancer care quality urban centers and rural, community-based practices. We must also focus on addressing country-specific unmet needs. Additionally, as we progress against our ambitious survival goal, and lives extend, we must prioritize the development of programs and services which assist the growing population of survivors returning to everyday life.

We stand together

We are four distinct organizations, all with extensive and complementary experience in helping patients and healthcare professionals manage lung cancer.

We stand together to better understand how the disease evolves, develop advanced therapeutic techniques, and ultimately empower and enable patients to live longer and better lives.


We cannot do this alone

We need your support. We are asking for like-minded members of medical, scientific and advocacy communities to join us in pursuit of our ambition


Improve the quality of lung cancer care

The ILC2 program invites patient and caregiver organizations (registered as non-profit in their country) to submit proposals for initiatives with the potential to transform patient care.



  1. (2020). All Cancers Factsheet. Available at: [Accessed February 2021].
  2. (2020). Lung Cancer Fact Sheet. Available at:,rate%20is%20only%205%20percent. [Accessed February 2021].
  3. Yousaf-Khan U, et al. Final Screening Round of the NELSON Lung Cancer Screening Trial: The Effect of a 2.5-year Screening Interval. Thorax. 2017;72:48–56.
  4. The National Lung Screening Trial Research Team. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409.
  5. Midthun D. Early detection of lung cancer. F1000Research. 2016;5(F1000 Faculty Rev):739
  6. NICE. The diagnosis and treatment of lung cancer (update). Available at Accessed August 2019
  7. Mathur S, et al. Personalised medicine could transform health care. Biomed Rep. 2017; (1) 3-5
  8. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  9. EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
  10. Cancer.Net. Lung Cancer - Non-Small Cell - Statistics. Available at Accessed May 2019
  11. Jemal a & Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278-1281
  12. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at Accessed August 2019
  13. Giroux, DJ et al. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology. 2018;13(6):801-809
  14. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  15. Mascaux C, et al. Personalised medicine for nonsmall cell lung cancer. European Respiratory Review. 2017;26
  16. IASLC Pathology Committee. Available at Accessed August 2019